GlaxoSmithKline Pharmaceuticals has informed that a meeting of the Board of Directors of the Company will be held on February 11, 2017, to consider and approve Un-Audited Financial Results for the quarter and nine months ended December 31, 2016 (Q3).
The above information is a part of company’s filings submitted to BSE.